KPV is the tripeptide Lys-Pro-Val — the three C-terminal residues (positions 11-13) of alpha-melanocyte stimulating hormone (α-MSH). In pre-clinical research, KPV has been studied for anti-inflammatory activity mediated through MC-1R receptor binding on intestinal epithelial cells and macrophages, with demonstrated NF-κB suppression and reduced cytokine release in cell culture and rodent models. Research use only — no human clinical trial data exists for KPV.

No. KPV has no FDA approval. It is under FDA Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026, for potential inclusion on the 503A Bulks List for wound healing indications. FDA staff's pre-meeting recommendation (June 29–30, 2026) was AGAINST adding KPV to the list. PCAC review is advisory and non-binding; FDA would need to complete formal rulemaking before any change to the 503A framework. KPV is currently a research chemical compound for laboratory use only.

No. KPV is not a Titan Peptide Lab catalog compound. For anti-inflammatory and wound healing research, Titan's closest in-stock compounds are BPC-157 vial ($54.99) — studied for gut epithelial healing and VEGFR2-Akt-eNOS angiogenesis — and TB-500 vial ($89.99) — studied for tissue repair via G-actin sequestration. These are not equivalent to KPV; the choice depends on the research model.

Why is the KPV COA verification harder than for a standard peptide?

At three residues (~356 Da), KPV is a very short peptide. The molecular weight difference between KPV and potential synthesis by-products or isomers is small, and some isomers share the same nominal mass. A plain HPLC purity percentage confirms that a major peak exists at a given retention time, not that the compound in that peak is specifically Lys-Pro-Val in the correct sequence. Credible KPV verification requires MS/MS fragmentation data confirming the b/y ion series for the Lys-Pro-Val sequence — the identity check, not just the purity check.

What is the difference between KPV and PT-141?

KPV (Lys-Pro-Val) and PT-141 (bremelanotide) are both compounds that interact with melanocortin receptors but are otherwise very different. KPV is a linear tripeptide targeting MC-1R on immune and epithelial cells, studied for anti-inflammatory activity. PT-141/bremelanotide is a cyclic heptapeptide targeting MC4R in the CNS, studied for sexual dysfunction (FDA-approved as Vyleesi for premenopausal HSDD). They share the melanocortin receptor superfamily but differ in size, structure, selectivity, and research application. Titan stocks PT-141 nasal spray ($69.99 RUO) — not KPV.

KPV sourcing guide · tripeptide identity & COA · research use only

Where to buy KPV peptide for research — and why a 3-mer tripeptide has a different COA problem than longer peptides.

KPV is the tripeptide Lys-Pro-Val — three amino acid residues forming the C-terminal α-MSH (alpha-melanocyte stimulating hormone) fragment, specifically residues 11–13 of the 13-amino-acid α-MSH sequence. In pre-clinical research contexts, KPV has been studied for anti-inflammatory activity in gut models (demonstrated binding to the MC-1R receptor, NF-κB suppression in intestinal epithelial cells, reduction of DSS-induced colitis in rodent models), wound healing, and skin barrier protection. As of July 23, 2026, KPV is among the seven peptides before the FDA Pharmacy Compounding Advisory Committee (PCAC) for potential inclusion on the 503A Bulks List for wound healing indications. This guide is written for researchers sourcing KPV for in-vitro laboratory research: what the sourcing landscape looks like, what a credible certificate of analysis must prove for a 3-mer peptide, and where Titan's honest in-stock catalog fits. All content is for laboratory research use only — no human-use, anti-inflammatory, wound-healing, or efficacy claim is made. RUO only.

BPC-157 vial — $54.99 (anti-inflammatory research, in stock)TB-500 vial — $89.99 (wound healing research, in stock)

What KPV is: α-MSH C-terminal tripeptide

Alpha-melanocyte stimulating hormone (α-MSH) is a 13-amino acid peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) that activates melanocortin receptors (MC-1R through MC-5R). The C-terminal tripeptide Lys-Pro-Val (positions 11-13) is KPV. Research interest in KPV centers on the hypothesis that this short fragment retains some of the anti-inflammatory activity of the parent molecule with a simpler synthesis: binding to MC-1R on intestinal epithelial cells and macrophages, suppressing NF-κB nuclear translocation, and reducing pro-inflammatory cytokine release (IL-6, IL-8, TNF-α). At three residues, KPV is among the smallest peptides actively studied in this field. Importantly: KPV is structurally distinct from PT-141 (bremelanotide, a cyclic heptapeptide targeting MC4R for different research purposes) and not related to Titan's in-stock peptides beyond both being research compounds.

Peptide identity verification →

The 3-mer COA problem: why a tripeptide is harder to verify than you think

A three-residue peptide weighs approximately 340–370 Da depending on the sequence. At that molecular weight, the mass spectrometry identity check that works well for 15-mer (BPC-157) or 28-mer (Thymosin α1) peptides runs into a specific problem: the molecular weight difference between KPV (Lys-Pro-Val, MW ~356 Da) and potential synthesis artifacts or isomers is small, and some isomers share the same nominal mass. An HPLC purity percentage for a tripeptide tells you how much material came off a peak, not whether that peak is actually your target sequence. The credible verification for KPV is MS/MS fragmentation — confirming the b/y ion series for Lys-Pro-Val in sequence — not just the parent ion mass, and certainly not a bare purity number. Any supplier whose KPV certificate shows only HPLC purity without sequencing-level MS data has not verified the identity of the compound.

Current-lot COA checklist →

PCAC July 2026: what the FDA review means for KPV sourcing

KPV is on the July 23, 2026 PCAC agenda for wound healing and inflammatory indications. The PCAC (Pharmacy Compounding Advisory Committee) is reviewing whether KPV should be added to the FDA 503A Bulks List — the list that allows licensed compounding pharmacies to compound bulk drug substances for individual patients. FDA staff's pre-meeting briefing (June 29–30, 2026) recommended AGAINST adding KPV to the 503A list. The PCAC vote is non-binding; formal rulemaking by FDA is still required before any change takes effect. Critically: the 503A Bulks List governs licensed compounding pharmacies serving patients. It does not regulate research-use-only (RUO) supply. Titan operates in the RUO research supply space, not as a compounding pharmacy. A PCAC vote — favorable or unfavorable — does not change the legal status of KPV as a research chemical compound for in-vitro laboratory use.

BPC-157 legal status 2026 →

Pre-clinical research context for KPV

The most cited KPV pre-clinical evidence centers on intestinal inflammation models. Research by Dalmasso et al. demonstrated that KPV reduced IL-6, IL-8, and NF-κB activation in Caco-2 intestinal epithelial cells and reduced DSS-induced colitis severity in mice. The MC-1R receptor on intestinal epithelia and macrophages is the proposed pharmacological target. KPV's short sequence raises the question of CNS penetration and systemic stability (tripeptides are typically degraded rapidly by peptidases) — some researchers have explored nanoparticle delivery systems to preserve KPV in the gut environment. This is pre-clinical and in-vitro literature; there is no published human clinical trial for KPV. All sourcing for research purposes only.

BPC-157 gut health research →

What Titan stocks for inflammatory and wound healing research

KPV is not a current Titan Peptide Lab catalog compound. Titan's RUO catalog includes BPC-157 (body protection compound, 15-mer, studied for gut epithelial healing, VEGFR2-Akt-eNOS angiogenesis, wound healing, and anti-inflammatory activity across multiple animal models) and TB-500 (Thymosin β4 fragment LKKTETQ, 7-mer, studied for tissue repair via actin sequestration and ILK/Akt survival signaling). These are in-stock, in-house-tested, with lot-matched release sheets available. For researchers whose KPV protocol can accommodate a longer peptide with broader mechanistic coverage, BPC-157 or TB-500 are the closest Titan alternatives in the anti-inflammatory/wound-healing research space. They are not equivalent compounds; the choice depends on the research question.

In-stock research peptides →

How to evaluate any KPV supplier

Given the tripeptide COA problem described above, the minimum bar for evaluating a KPV research supply is: (1) MS/MS fragmentation data confirming the Lys-Pro-Val b/y ion series — not just the parent molecular weight. (2) A lot number on the certificate that matches the lot on the vial you received. (3) HPLC purity of ≥98% with the chromatogram attached, not just the number. (4) Statement of C-terminal form — KPV as a free acid vs KPV-amide are different compounds; which termination is specified matters for receptor binding studies. (5) A dated certificate with a physical address for the testing laboratory. Any of these missing should be a red flag regardless of how the badge looks on the product page.

Janoshik COA verification guide →

The detail, in plain terms

KPV sourcing reference.

KPV = Lys-Pro-Val, α-MSH C-terminal tripeptide. Research only. Under FDA PCAC review July 23, 2026. Not a Titan catalog compound — see BPC-157 and TB-500 for in-stock anti-inflammatory/wound-healing research peptides.

Full name: Lysine-Proline-Valine (Lys-Pro-Val), α-MSH residues 11-13.
MW: ~356 Da (free acid). Very short tripeptide — COA must include MS/MS sequencing, not just parent mass.
Receptor: MC-1R (melanocortin receptor 1) on intestinal epithelial cells and macrophages.
Research models: NF-κB suppression in Caco-2 cells; DSS-induced colitis (rodent); wound healing; skin models.
PCAC status: Under July 23, 2026 FDA PCAC review for wound healing; FDA staff recommended AGAINST 503A listing.
Titan supply: NOT stocked — closest in-stock analogs for wound/anti-inflammatory research: BPC-157 vial $54.99 + TB-500 vial $89.99.

Questions researchers ask

Before you order.

What is KPV peptide?: KPV is the tripeptide Lys-Pro-Val — the three C-terminal residues (positions 11-13) of alpha-melanocyte stimulating hormone (α-MSH). In pre-clinical research, KPV has been studied for anti-inflammatory activity mediated through MC-1R receptor binding on intestinal epithelial cells and macrophages, with demonstrated NF-κB suppression and reduced cytokine release in cell culture and rodent models. Research use only — no human clinical trial data exists for KPV.
Is KPV FDA-approved?: No. KPV has no FDA approval. It is under FDA Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026, for potential inclusion on the 503A Bulks List for wound healing indications. FDA staff's pre-meeting recommendation (June 29–30, 2026) was AGAINST adding KPV to the list. PCAC review is advisory and non-binding; FDA would need to complete formal rulemaking before any change to the 503A framework. KPV is currently a research chemical compound for laboratory use only.
Does Titan sell KPV?: No. KPV is not a Titan Peptide Lab catalog compound. For anti-inflammatory and wound healing research, Titan's closest in-stock compounds are BPC-157 vial ($54.99) — studied for gut epithelial healing and VEGFR2-Akt-eNOS angiogenesis — and TB-500 vial ($89.99) — studied for tissue repair via G-actin sequestration. These are not equivalent to KPV; the choice depends on the research model.
Why is the KPV COA verification harder than for a standard peptide?: At three residues (~356 Da), KPV is a very short peptide. The molecular weight difference between KPV and potential synthesis by-products or isomers is small, and some isomers share the same nominal mass. A plain HPLC purity percentage confirms that a major peak exists at a given retention time, not that the compound in that peak is specifically Lys-Pro-Val in the correct sequence. Credible KPV verification requires MS/MS fragmentation data confirming the b/y ion series for the Lys-Pro-Val sequence — the identity check, not just the purity check.
What is the difference between KPV and PT-141?: KPV (Lys-Pro-Val) and PT-141 (bremelanotide) are both compounds that interact with melanocortin receptors but are otherwise very different. KPV is a linear tripeptide targeting MC-1R on immune and epithelial cells, studied for anti-inflammatory activity. PT-141/bremelanotide is a cyclic heptapeptide targeting MC4R in the CNS, studied for sexual dysfunction (FDA-approved as Vyleesi for premenopausal HSDD). They share the melanocortin receptor superfamily but differ in size, structure, selectivity, and research application. Titan stocks PT-141 nasal spray ($69.99 RUO) — not KPV.